Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark McFarland

Orthopaedic Surgery of the Spine Newport News, VA Doctor of Osteopathy

NPI 1841352671 CMS profile 83856

250 Nat Turner Blvd S, Newport News, VA 23606

Open in the dashboard

General payments

$9,625

138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark McFarland of Newport News, VA is reported in the CMS Open Payments database as having received $9,625 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,776 23
2024 General $1,993 27
2023 General $165 7
2022 General $273 21
2021 General $1,325 41
2020 General $236 7
2019 General $1,857 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark McFarland
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Mark McFarland were reported at $3,776. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Mark McFarland Orthopaedic Surgery of the Spine median Middle half National median
2019 $1,857 $2,106 $337–$18,608 $163
2020 $236 $1,213 $156–$15,082 $114
2021 $1,325 $1,834 $271–$15,617 $132
2022 $273 $2,015 $320–$17,036 $149
2023 $165 $1,925 $336–$14,599 $160
2024 $1,993 $2,110 $341–$12,483 $164
2025 $3,776 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alphatec Spine, Inc $2,751 9 payments
  2. Spinefrontier, Inc. $1,715 6 payments
  3. Boston Scientific Corporation $1,370 9 payments
  4. Medtronic, Inc. $1,160 51 payments
  5. Providence Medical Technology, Inc. $706 9 payments
  6. Medacta USA, Inc. $545 6 payments
  7. Cerapedics, Inc. $208 7 payments
  8. Spineology Inc. $163 4 payments
  9. Globus Medical, Inc. $126 5 payments
  10. Exactech, Inc. $125 1 payment
  11. Other $756 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,516 15 payments
  2. Food and Beverage $3,382 116 payments
  3. Consulting Fee $1,663 1 payment
  4. Education $65 6 payments
Products named General payments · program years 2019–2025
  1. Other - Miscellaneous $2,751 9 payments
  2. PLIFT $1,696 5 payments
  3. NanoFuse $1,696 5 payments
  4. ACIFT Solofuse $1,696 5 payments
  5. PedFuse Remind $1,696 5 payments
  6. Intracept $1,351 8 payments
  7. MYSPINE $545 6 payments
  8. I-FACTOR PEPTIDE ENHANCED BONE GRAFT Peptide Enhanced Bone Graft $208 7 payments
  9. I-FACTOR PEPTIDE ENHANCED BONE GRAFT Peptide Enhanced Bone Graft $208 7 payments
  10. I-FACTOR PEPTIDE ENHANCED BONE GRAFT Peptide Enhanced Bone Graft $208 7 payments
  11. Other $2,291 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,562

Median for Osteopathic Manipulative Medicine: 311

Drug cost

$15,425

Median for Osteopathic Manipulative Medicine: $11,323

Branded share of claims

11%

Median for Osteopathic Manipulative Medicine: 19.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Generic 42 $3,874
Methocarbamol Generic 231 $2,987
Diclofenac Sodium Generic 123 $1,759
Methylprednisolone Generic 149 $974
Gabapentin Generic 174 $711
Tizanidine Hcl Generic 84 $708
Celecoxib Generic 19 $638
Cyclobenzaprine Hcl Generic 57 $599
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 75 $520
Acetaminophen-Codeine Acetaminophen With Codeine Brand 67 $482

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$794,489

Of which drugs: $39,248

Medicare patients

954

Average age 76

Services billed

56,904

563 women, 391 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 30%
Ischemic heart disease 25%
Chronic kidney disease 21%
Depression 21%
Osteoporosis 21%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 61 276 $15,648
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 19 88 $8,695
Injection, methylprednisolone acetate, 1 mg J1010 Office 207 31,960 $3,321
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 11 34 $3,267
Injection, methylprednisolone acetate, 40 mg J1030 Office 81 318 $1,530
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 419 10,629 $949
Injection, gadobenate dimeglumine (multihance), per ml A9577 Office 46 410 $566

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record